Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial

Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial

Introduction Sepsis remains the major cause of death among hospitalised patients in intensive care. While targeting sepsis-causing pathogens with source control or antimicrobials has had a dramatic impact on morbidity and mortality of sepsis patients, this strategy remains insufficient for about one...

Full description

Bibliographic Details
Main Authors: Peter Schlattmann, Thomas Lehmann, Tim Rahmel, Johannes Roth, Peter Kranke, Frank M Brunkhorst, Andreas Greinacher, Patrick Meybohm, Philipp Helmer, Stefan Hagel, Florian Rißner, Michael Bauer, Matthias Gründling, Sven-Olaf Kuhn, Christian Fuchs, Luis Ferreira Moita, Frank Bloos, Matthias Michael, Ulrike Schumacher, Matthias Unterberg, Daniel Thomas-Rüddel, Christiane Helbig, Johannes Ehler, Heiko Schenk, Thomas Köcher, Markus Gräler, Ann-Julika Heger, Sebastian Weis, Karen Dlubatz, Jakob Hammersen, Katja Leonhardt, René Markgraf, Franziska Röstel, Nicole Schwarze, Mariann Städtler, Wolfgang Vivas-Varela, Andre Hagedorn, Andrea Wittkowski, Florian Rumpf, Tobias Haas, Sebastian Hottenrott, Eva Kranke, Marianne Neuf, Anke Reppchen, Daniel Röder, Julius Schmidt
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/4/e075158.full

Internet

https://bmjopen.bmj.com/content/14/4/e075158.full

Similar Items